Key Drivers
- Strong Liquidity
- Cash Flow Deterioration
- Rising Leverage
AIAI Summary
GeneDx is now a cash-conversion and execution thesis—not just a genomics-growth story—so investors should wait for evidence that collections normalize and free cash flow recovers before underwriting its premium valuation, despite strong clinical-volume growth and margins.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Cash Flow Deterioration
- •Rising Leverage
WGS retains solid liquidity and high gross margins, but worsening losses, negative free cash flow, rising leverage, and an expensive valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Strong upward momentum
- •$105 resistance test
- •Elevated volatility
WGS remains bullish after a ~16% last-month gain, but watch $105 resistance and $97.42 support amid elevated pullback risk.
Sharp swing from $104.95 to $97.42 highlights volatility risk
Sentiment & News
Key News Insights:
- •Earnings Momentum
- •Clinical Validation
- •Partnership Expansion
GeneDx's positive earnings outlook, rapid-genome sequencing validation, and new NPC partnership strengthen its diagnostic-growth narrative despite competitive genomics activity.
These developments could support a constructive outlook for WGS by reinforcing adoption, access, and diagnostic leadership
Similar Companies in Healthcare
Other companies in the same sector with AI ratings